Photosensitizer Tailored Surface Functionalized Carbon Dots for Visible Light Induced Targeted Cancer Therapy

Chowdhury, Monalisa ; Sarkar, Saheli ; Das, Prasanta Kumar (2019) Photosensitizer Tailored Surface Functionalized Carbon Dots for Visible Light Induced Targeted Cancer Therapy ACS Applied Bio Materials, 2 (11). pp. 4953-4965. ISSN 2576-6422

Full text not available from this repository.

Official URL: http://doi.org/10.1021/acsabm.9b00689

Related URL: http://dx.doi.org/10.1021/acsabm.9b00689

Abstract

Herein, a photosensitizer (riboflavin) tailored surface functionalized carbon dot (RCD1s) was designed to utilize it in visible light induced targeted cancer therapy. At first, phenylboronic acid appended biotinylated blue emitting carbon dot (CD1s) was synthesized. Riboflavin having “diol” moiety was covalently linked with this CD1s to prepare RCD1s by using complementary boronate-diol linkage. Lewis acid–base interaction facilitated the covalent linkage formation between the surface functionalizing agent of CD1s and riboflavin to develop water-soluble, green emitting RCD1s. Interestingly, this newly synthesized RCD1s has the ability to produce reactive oxygen species (ROS) such as hydroxyl and superoxide radicals under exposure of visible light (wavelength: 460–490 nm). These ROS also can destroy the structure of DNA by oxidative pathway. Thus, under irradiation of visible light (wavelength: 460–490 nm), RCD1s was found to kill HeLa and B16F10 melanoma cells over noncancer cell NIH3T3 by ∼5-fold higher efficacy through ROS induced oxidative DNA damage. The presence of biotin on the surface of the riboflavin tethered carbon dot is essential for the selective killing of cancer cells over normal cells. In the presence of UV light (340–420 nm), RCD1s showed no notable killing of cancer cells as well as normal cells. Besides, RCD1s in the presence of visible light selectively stained HeLa and B16F10 cells over noncancerous cell NIH3T3 by exploiting its fluorescence and cancer cell targeting moiety, biotin. Hence, the newly developed RCD1s can be utilized in theranostic applications including bioimaging and selective killing of cancer cells in the presence of visible light (460–490 nm).

Item Type:Article
Source:Copyright of this article belongs to American Chemical Society.
ID Code:123615
Deposited On:08 Oct 2021 06:17
Last Modified:08 Oct 2021 06:17

Repository Staff Only: item control page